MA54709A - Traitement de maux de tête dus à un usage abusif de médicaments à l'aide d'anticorps anti-cgrp ou anti-cgrp-r - Google Patents

Traitement de maux de tête dus à un usage abusif de médicaments à l'aide d'anticorps anti-cgrp ou anti-cgrp-r

Info

Publication number
MA54709A
MA54709A MA054709A MA54709A MA54709A MA 54709 A MA54709 A MA 54709A MA 054709 A MA054709 A MA 054709A MA 54709 A MA54709 A MA 54709A MA 54709 A MA54709 A MA 54709A
Authority
MA
Morocco
Prior art keywords
cgrp
antibodies
treatment
headaches due
drug overuse
Prior art date
Application number
MA054709A
Other languages
English (en)
Inventor
Roger K Cady
Joseph Hirman
Lahar Mehta
Barbara Schaeffler
Jeffrey T L Smith
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA54709A publication Critical patent/MA54709A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA054709A 2019-01-08 2020-01-08 Traitement de maux de tête dus à un usage abusif de médicaments à l'aide d'anticorps anti-cgrp ou anti-cgrp-r MA54709A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962789828P 2019-01-08 2019-01-08
US201962840967P 2019-04-30 2019-04-30
US201962841585P 2019-05-01 2019-05-01
US201962872983P 2019-07-11 2019-07-11

Publications (1)

Publication Number Publication Date
MA54709A true MA54709A (fr) 2022-04-13

Family

ID=71404208

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054709A MA54709A (fr) 2019-01-08 2020-01-08 Traitement de maux de tête dus à un usage abusif de médicaments à l'aide d'anticorps anti-cgrp ou anti-cgrp-r

Country Status (24)

Country Link
US (2) US20200216525A1 (fr)
EP (1) EP3908607A4 (fr)
JP (2) JP2022516957A (fr)
KR (1) KR20210114002A (fr)
CN (2) CN113272324A (fr)
AU (1) AU2020207299A1 (fr)
BR (1) BR112020018044A2 (fr)
CA (1) CA3123292A1 (fr)
CL (1) CL2021001813A1 (fr)
CO (1) CO2021008665A2 (fr)
DO (1) DOP2021000145A (fr)
EC (1) ECSP21052193A (fr)
GE (2) GEP20257804B (fr)
IL (1) IL284677A (fr)
JO (1) JOP20210166A1 (fr)
MA (1) MA54709A (fr)
MX (1) MX2021008268A (fr)
NI (1) NI202100063A (fr)
PE (1) PE20211708A1 (fr)
PH (1) PH12021551494A1 (fr)
SG (1) SG11202106878XA (fr)
TW (1) TW202030205A (fr)
UA (1) UA129265C2 (fr)
WO (1) WO2020146535A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ732970A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
CN103957935B (zh) 2011-05-20 2018-04-03 奥尔德生物控股有限责任公司 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
EP3662932B1 (fr) 2011-05-20 2021-04-07 H. Lundbeck A/S Compositions anti-cgrp et leur utilisation
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
CA3077973A1 (fr) 2020-04-06 2021-10-06 H. Lundbeck A/S Traitement du symptome le plus perturbant associe a la migraine au moyen d`anticorps anti-cgrp
JP2024532143A (ja) * 2021-08-27 2024-09-05 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を使用した群発頭痛の治療
EP4570913A1 (fr) * 2022-08-11 2025-06-18 Shanghai Junshi Biosciences Co., Ltd. Anticorps anti-cgrp et utilisation
CN118476508A (zh) * 2024-06-27 2024-08-13 中国人民解放军总医院第一医学中心 一种基于疾病发生特点的药物过度使用性头痛动物模型的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112723A2 (fr) * 2003-06-20 2004-12-29 Ronald Aung-Din Therapie locale pour le traitement des migraines, des claquages musculaires, des spasmes musculaires, de la spasticite et d'etats apparentes
NZ732970A (en) * 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EP3662932B1 (fr) * 2011-05-20 2021-04-07 H. Lundbeck A/S Compositions anti-cgrp et leur utilisation
CN103585449B (zh) * 2013-10-23 2016-06-22 高丽丽 用于治疗偏头痛的中药组合物
JP6752223B2 (ja) * 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
KR20220031944A (ko) * 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
US11639380B2 (en) * 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies

Also Published As

Publication number Publication date
CO2021008665A2 (es) 2021-07-19
DOP2021000145A (es) 2021-10-31
GEP20257804B (en) 2025-10-10
JP2025032102A (ja) 2025-03-11
PH12021551494A1 (en) 2023-05-08
EP3908607A4 (fr) 2022-10-05
AU2020207299A1 (en) 2021-08-26
CN113272324A (zh) 2021-08-17
BR112020018044A2 (pt) 2021-08-10
IL284677A (en) 2021-08-31
CL2021001813A1 (es) 2021-12-24
NI202100063A (es) 2021-12-01
PE20211708A1 (es) 2021-09-01
ECSP21052193A (es) 2021-08-31
TW202030205A (zh) 2020-08-16
CN119303074A (zh) 2025-01-14
GEAP202515689A (en) 2025-04-25
MX2021008268A (es) 2021-08-05
US20240343784A1 (en) 2024-10-17
UA129265C2 (uk) 2025-03-05
US20200216525A1 (en) 2020-07-09
JOP20210166A1 (ar) 2023-01-30
EP3908607A1 (fr) 2021-11-17
KR20210114002A (ko) 2021-09-17
WO2020146535A1 (fr) 2020-07-16
JP2022516957A (ja) 2022-03-03
CA3123292A1 (fr) 2020-07-16
SG11202106878XA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MA54709A (fr) Traitement de maux de tête dus à un usage abusif de médicaments à l'aide d'anticorps anti-cgrp ou anti-cgrp-r
EP3908606A4 (fr) Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
EP3755805A4 (fr) Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain
EA201992163A1 (ru) АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ
EP3746119A4 (fr) Procédés de traitement du cancer ou d'une infection à l'aide d'une combinaison d'un anticorps anti-pd -1, d'un anticorps anti-lag3 et d'un anticorps anti-tigit
MA51916A (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
EP3645039A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc
MA42657A (fr) Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
MA38478A1 (fr) Anticorps anti-pac1 humains
MA32948B1 (fr) Anticorps anti-pd-l1 et leur utilisation pour ameliorer la fonction des lymphocytes t
EP2860188A4 (fr) Polypeptides et anticorps pour le traitement d'une infection par le vbh et maladies associées
EP3573658A4 (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MA56047A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
EA201791590A1 (ru) Антитела к tau и их применение
PT4027983T (pt) Tratamento de doenças neovasculares oculares com utilização de variantes de aav2 que codificam aflibercept
EP2753611A4 (fr) Composés benzofuranes substitués et leurs procédés d'utilisation pour le traitement de maladies virales
EP3927729A4 (fr) Formulation d'anticorps thérapeutique
EP3773686A4 (fr) Agents au phosphatase alcaline pour le traitement de troubles dus à une exposition à des radiations
EP4034530A4 (fr) Inhibiteurs de la protéine kinase i interagissant avec des récepteurs pour le traitement d'une maladie
EP3877418A4 (fr) Schéma posologique d'anticorps anti-tigit pour le traitement du cancer
EP2858674A4 (fr) Composition d'anticorps pour la prévention ou le traitement d'une infection par un virus mutant de l'hépatite b
EP3902826A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de l'athérosclérose